| From: |
|
Dr June Raine, Director, Vigilance and Risk Management of Medicines
|
|
|
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- CMO Urgent Messages - Recipients on Public Health Link
- NHS Trusts (England) - Chief Executive
|
|
|
- Clinical Commissioning Groups
- Social Care Providers (registered with CAS)
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- Director of Public Health
|
| Action category: |
|
Non urgent (cascade within 48 hours)
|
| Title: |
|
Valproate and risk of abnormal pregnancy outcomes: new communication materials
|
| Broadcast content: |
|
In January 2015 we wrote to inform you that children exposed to valproate in utero are at high risk of developmental disorders and congenital malformations. To further improve awareness of the risks of valproate in pregnancy we are asking that you use the new communication materials described in the attached letter to support discussion of these risks with women of childbearing potential and girls who take valproate.
|
| Additional information: |
|
This information is especially important for healthcare professionals involved in the management of epilepsy or bipolar disorder. Regional Offices: please cascade to general practice and pharmacy.
|
| Cascade to: |
|
- #GP#
- #ACCIDENTEMERGENCY#
- #COMMUNITYPHARMACISTS#
- #DISPENSING GP#
- #NURSES#
- #HospitalPharmacy#
|